S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Tamara Fountain, a director at RxSight, Inc. (NASDAQ:RXST), recently sold a portion of her holdings in the company. According to a recent SEC filing, Fountain sold 7,000 shares of RxSight common stock on March 12, 2025. The shares were sold at a weighted average price of $25.7145, amounting to a total transaction value of $180,001. The transaction comes as RxSight, currently valued at $1.02 billion, has seen its stock decline over 52% in the past six months and trades near its 52-week low of $24.64. InvestingPro analysis indicates the stock is currently overvalued.
These transactions were conducted under a pre-arranged trading plan established on December 11, 2024, as part of a Rule 10b5-1 trading plan. After this sale, Fountain holds 24,793 shares of RxSight directly. Get deeper insights into RXST’s insider trading patterns and comprehensive financial analysis with InvestingPro, which offers exclusive access to detailed Pro Research Reports covering 1,400+ US stocks.
In other recent news, RxSight Inc. reported a strong performance for the fourth quarter of 2024, with earnings per share (EPS) of $0.03, surpassing expectations of -$0.17. The company’s revenue for the quarter was $40.2 million, reflecting a 41% year-over-year increase, although slightly below the forecasted $40.39 million. Full-year revenue reached $139.9 million, marking a 57% rise from the previous year. Looking ahead, RxSight has reaffirmed its 2025 revenue guidance, projecting between $185 million and $197 million, translating to a 32% to 41% increase. Jefferies and BTIG both adjusted their price targets for RxSight to $50 and $44, respectively, while maintaining a Buy rating. These revisions follow the company’s earnings report and guidance for 2025, which are seen as positive indicators for future growth. RxSight plans to expand its market reach and product offerings, with anticipated international approvals and new functionalities for its Light Delivery Devices (LDDs) expected to boost growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.